HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsPricing
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

SUPN

Supernus Pharmaceuticals Inc

Last Close
Sep 12  •  04:00PM ET
45.46
Dollar change
-1.20
Percentage change
-2.57 %
Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD
Peers: NBIX ACAD TEVA UTHR INSM AXNX PTCT DRRX MNKD XENE
 | Held by: IJR IWM VTI VB VBR SPSM VXF IWN DFAT AVUV
Scroll to Statements
IndexRUT P/E39.73 EPS (ttm)1.14 Insider Own5.68% Shs Outstand56.12M Perf Week-1.17%
Market Cap2.55B Forward P/E18.66 EPS next Y2.44 Insider Trans-8.18% Shs Float52.90M Perf Month6.61%
Enterprise Value2.06B PEG5.91 EPS next Q0.29 Inst Own106.16% Short Float9.08% Perf Quarter38.72%
Income64.50M P/S3.83 EPS this Y-29.26% Inst Trans0.72% Short Ratio5.86 Perf Half Y45.85%
Sales665.12M P/B2.40 EPS next Y9.60% ROA4.78% Short Interest4.80M Perf YTD25.72%
Book/sh18.96 P/C4.88 EPS next 5Y6.72% ROE6.38% 52W High46.78 -2.83% Perf Year35.74%
Cash/sh9.32 P/FCF13.71 EPS past 3/5Y10.33% -8.87% ROIC5.93% 52W Low29.16 55.90% Perf 3Y32.85%
Dividend Est.- EV/EBITDA13.85 Sales past 3/5Y4.51% 11.00% Gross Margin76.41% Volatility2.25% 2.50% Perf 5Y112.33%
Dividend TTM- EV/Sales3.09 EPS Y/Y TTM1145.24% Oper. Margin10.21% ATR (14)1.17 Perf 10Y131.23%
Dividend Ex-Date- Quick Ratio2.43 Sales Y/Y TTM5.55% Profit Margin9.70% RSI (14)64.24 Recom1.80
Dividend Gr. 3/5Y- - Current Ratio2.58 EPS Q/Q11.14% SMA201.71% Beta0.78 Target Price43.80
Payout0.00% Debt/Eq0.03 Sales Q/Q-1.71% SMA5016.09% Rel Volume0.50 Prev Close46.66
Employees674 LT Debt/Eq0.02 EarningsAug 05 AMC SMA20028.38% Avg Volume818.69K Price45.46
IPOMay 01, 2012 Option/ShortYes / Yes EPS/Sales Surpr.93.28% 7.39% Trades Volume415,075 Change-2.57%
Date Action Analyst Rating Change Price Target Change
Jul-30-25Upgrade Cantor Fitzgerald Neutral → Overweight $42
Feb-19-25Downgrade Cantor Fitzgerald Overweight → Neutral $57 → $36
Jan-06-25Initiated Cantor Fitzgerald Overweight $57
Sep-11-24Downgrade Piper Sandler Overweight → Neutral $41 → $36
Jan-03-23Resumed Jefferies Buy $44 → $45
Dec-01-21Resumed Jefferies Buy $40 → $44
Apr-13-21Upgrade Jefferies Hold → Buy $25 → $40
Jun-16-20Upgrade Piper Sandler Neutral → Overweight $25 → $31
Jun-15-20Resumed Jefferies Hold $24
Nov-08-19Downgrade Berenberg Buy → Hold
Show Previous Ratings
Aug-27-25 04:15PM
Supernus Pharmaceuticals to Participate in September Investor Conferences
(GlobeNewswire)
Aug-13-25 12:12AM
5 Insightful Analyst Questions From Supernus Pharmaceuticals's Q2 Earnings Call
(StockStory)
Aug-12-25 11:43PM
SUPN Q2 Deep Dive: Growth Drivers Shift to New Portfolio as Legacy Products Fade
(StockStory)
Aug-11-25 08:00AM
Here's Third Avenue Small-Cap Value Fund's Update on Supernus Pharmaceuticals (SUPN)
(Insider Monkey)
Aug-07-25 02:00PM
Supernus Pharmaceuticals Stock Scores RS Rating Upgrade
(Investor's Business Daily)
01:20PM Loading…
Aug-06-25 01:20PM
Why Are Supernus Pharmaceuticals (SUPN) Shares Soaring Today
(StockStory) +13.08%
03:27AM
Supernus Pharmaceuticals Inc (SUPN) Q2 2025 Earnings Call Highlights: Innovation and Strategic ...
(GuruFocus.com)
Aug-05-25 08:30PM
Supernus (SUPN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
(Zacks)
06:35PM
Supernus Pharmaceuticals (SUPN) Surpasses Q2 Earnings and Revenue Estimates
(Zacks)
06:18PM
Supernus Pharmaceuticals (NASDAQ:SUPN) Beats Expectations in Strong Q2, Guides for Strong Full-Year Sales
(StockStory)
05:32PM
Supernus: Q2 Earnings Snapshot
(Associated Press Finance)
04:05PM
Supernus Announces Second Quarter 2025 Financial Results
(GlobeNewswire)
Aug-03-25 11:08PM
Supernus Pharmaceuticals (SUPN) Reports Earnings Tomorrow: What To Expect
(StockStory)
Aug-01-25 07:09AM
Supernus strengthens neuropsychiatric portfolio with Sage Therapeutics
(Pharmaceutical Technology)
Jul-31-25 10:48AM
Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up
(Zacks)
08:44AM Loading…
08:44AM
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
(GlobeNewswire)
Jul-30-25 04:05PM
Sage Therapeutics Announces Second Quarter 2025 Financial Results
(Business Wire)
12:16PM
Why Supernus Pharmaceuticals (SUPN) Stock Is Up Today
(StockStory)
Jul-28-25 10:24AM
Biogen Gears Up to Report Q2 Earnings: Here's What to Expect
(Zacks)
08:25AM
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
(GlobeNewswire)
Jul-24-25 11:33PM
Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)
(StockStory)
Jul-22-25 04:30PM
Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025
(GlobeNewswire)
Jul-18-25 03:10PM
Why Supernus Pharmaceuticals (SUPN) Shares Are Falling Today
(StockStory)
Jul-14-25 12:31AM
1 Stock Under $50 with Exciting Potential and 2 to Turn Down
(StockStory)
Jun-30-25 01:43PM
Sage to lay off most staff amid Supernus buyout
(BioPharma Dive)
Jun-27-25 05:23AM
Supernus Pharmaceuticals's Q1 Earnings Call: Our Top 5 Analyst Questions
(StockStory)
Jun-18-25 09:45AM
H.C. Wainwright sees potential competition for Sage from Biogen
(TipRanks)
Jun-17-25 02:36PM
SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal
(Zacks)
09:16AM
Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus
(TipRanks)
Jun-16-25 04:21PM
Supernus Pharmaceuticals Snaps Up Beleaguered Sage Therapeutics
(Investor's Business Daily)
11:43AM Loading…
11:43AM
Supernus makes depression drug play with $795m Sage buyout
(Pharmaceutical Technology)
09:16AM
Beleaguered Sage Snapped Up In Deal Worth Up To $561 Million
(Investor's Business Daily)
07:42AM
Sage Therapeutics Stock Soars 35% After Sale to Supernus Pharmaceuticals. What We Know.
(Barrons.com)
07:00AM
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio
(GlobeNewswire)
May-29-25 08:30AM
Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree Content Series with Supernus Pharmaceuticals
(GlobeNewswire)
May-28-25 04:05PM
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference
(GlobeNewswire)
04:05PM
Supernus Announces Paragraph IV ANDA Filings for Qelbree
(GlobeNewswire)
May-20-25 08:30AM
Busy Philipps Empowers Women with ADHD to Go from Feeling Misrepresented to Being 'Ms. Represented' in First-of-its-Kind Campaign with Supernus Pharmaceuticals
(GlobeNewswire)
May-14-25 02:29PM
Is the Options Market Predicting a Spike in Supernus Pharmaceuticals (SUPN) Stock?
(Zacks)
May-07-25 03:20AM
Supernus Pharmaceuticals Inc (SUPN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ...
(GuruFocus.com)
12:34AM
3 Stocks Under $50 That Concern Us
(StockStory)
May-06-25 10:55PM
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2025 Earnings Call Transcript
(Seeking Alpha)
07:00PM
Supernus (SUPN) Reports Q1 Earnings: What Key Metrics Have to Say
(Zacks)
05:30PM
Supernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Surpass Estimates
(Zacks)
04:08PM
Supernus Announces First Quarter 2025 Financial Results
(GlobeNewswire)
Apr-30-25 07:28AM
Supernus: New Direction Beckons After MDD Drug Fail (Rating Downgrade)
(Seeking Alpha)
Apr-29-25 09:05AM
3 of Wall Street's Favorite Stocks with Questionable Fundamentals
(StockStory)
Apr-28-25 12:00PM
What Makes Supernus (SUPN) a New Buy Stock
(Zacks)
Apr-24-25 07:46AM
Johnson & Johnson Just Proved The Bears Wrong Again
(Seeking Alpha)
Apr-23-25 05:14PM
Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025
(GlobeNewswire)
Apr-17-25 11:08AM
Is Supernus Pharmaceuticals, Inc. (SUPN) the Best Pharma Stock to Buy for Long Term Growth?
(Insider Monkey)
Apr-04-25 05:13AM
Supernus Pharmaceuticals (SUPN): Buy, Sell, or Hold Post Q4 Earnings?
(StockStory)
Mar-25-25 12:53PM
IBD 50's Axsome Therapeutics Dives On Mixed ADHD Results. Why Analysts Aren't Worried.
(Investor's Business Daily)
Mar-17-25 09:35AM
Down -20.07% in 4 Weeks, Here's Why Supernus (SUPN) Looks Ripe for a Turnaround
(Zacks)
Mar-14-25 05:01AM
Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals Stocks
(StockStory)
Mar-13-25 09:00AM
3 Small-Cap Stocks Skating on Thin Ice
(StockStory)
Mar-06-25 07:24PM
Supernus Pharmaceuticals, Inc. (SUPN): Among the Cash-Rich Small Cap Stocks To Invest In According To Analysts
(Insider Monkey)
Mar-04-25 04:30PM
Supernus to Participate in Two Upcoming Investor Conferences
(GlobeNewswire)
04:06AM
Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks
(StockStory)
04:03AM
Branded Pharmaceuticals Stocks Q4 In Review: Bristol-Myers Squibb (NYSE:BMY) Vs Peers
(StockStory)
Mar-02-25 12:16PM
Is Supernus Pharmaceuticals, Inc. (SUPN) the Best Small Cap Pharma Stock to Buy Now?
(Insider Monkey)
Feb-27-25 08:30AM
Supernus to Participate in the TD Cowen 45th Annual Health Care Conference
(GlobeNewswire)
Feb-26-25 12:51PM
Q4 2024 Supernus Pharmaceuticals Inc Earnings Call
(Thomson Reuters StreetEvents)
02:14AM
Supernus Pharmaceuticals Inc (SUPN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ...
(GuruFocus.com)
Feb-25-25 06:30PM
Supernus (SUPN) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
(Zacks)
05:45PM
Supernus Pharmaceuticals (SUPN) Beats Q4 Earnings and Revenue Estimates
(Zacks)
05:28PM
Supernus Pharmaceuticals (NASDAQ:SUPN) Delivers Strong Q4 Numbers
(StockStory)
04:53PM
Supernus: Q4 Earnings Snapshot
(Associated Press Finance)
04:01PM
Supernus Announces Fourth Quarter and Full Year 2024 Financial Results
(GlobeNewswire)
Feb-24-25 08:06AM
What To Expect From Supernus Pharmaceuticalss (SUPN) Q4 Earnings
(StockStory)
Feb-19-25 10:29AM
Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial
(Benzinga) -15.67%
Feb-18-25 04:25PM
Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression
(GlobeNewswire)
Feb-11-25 04:30PM
Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
(GlobeNewswire)
Feb-06-25 12:00PM
Supernus (SUPN) Moves to Strong Buy: Rationale Behind the Upgrade
(Zacks)
07:48AM
Supernus wins FDA approval for Parkinsons pump on fourth try
(Pharmaceutical Technology)
Feb-04-25 09:00AM
Supernus Announces FDA Approval of ONAPGO (apomorphine hydrochloride) for Parkinson's Disease
(GlobeNewswire) +7.07%
Jan-30-25 06:22AM
7MM PD market to grow by $4.5bn between 2023 and 2033
(Clinical Trials Arena)
Jan-27-25 08:00AM
Supernus Announces Label Update for Non-Stimulant ADHD Treatment, Qelbree , Including New Pharmacodynamic Data and Information for Breastfeeding Women
(GlobeNewswire)
Dec-16-24 04:30PM
Knight Therapeutics Announces Filing of New Drug Submission for Qelbree (viloxazine) in Canada
(GlobeNewswire)
Nov-26-24 05:00PM
Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference
(GlobeNewswire)
Nov-13-24 04:30PM
Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference
(GlobeNewswire)
Nov-05-24 08:00AM
Supernus Pharmaceuticals Inc (SUPN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...
(GuruFocus.com)
Nov-04-24 08:00PM
Supernus (SUPN) Reports Q3 Earnings: What Key Metrics Have to Say
(Zacks)
07:35PM
Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates
(Zacks)
06:33PM
Supernus: Q3 Earnings Snapshot
(Associated Press Finance)
04:05PM
Supernus Announces Third Quarter 2024 Financial Results
(GlobeNewswire)
Oct-31-24 04:10PM
Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024
(GlobeNewswire)
Oct-21-24 04:25PM
Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results
(GlobeNewswire)
Oct-18-24 08:31PM
Supernus depression drug improved symptoms in two hours in Phase IIa study
(Clinical Trials Arena)
Oct-17-24 04:05PM
Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder
(GlobeNewswire)
Oct-10-24 05:12PM
Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder
(GlobeNewswire)
Oct-09-24 05:07PM
Supernus Pharmaceuticals Inc (SUPN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...
(GuruFocus.com)
Sep-24-24 07:30AM
Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree
(GlobeNewswire)
Sep-19-24 04:30PM
Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
(GlobeNewswire)
Sep-16-24 10:50AM
Supernus Pharmaceuticals (SUPN) Slid on Disappointing Progress Report on a Key Drug
(Insider Monkey)
Sep-11-24 02:38PM
ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug
(Benzinga) -7.20%
Aug-28-24 04:15PM
Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
(GlobeNewswire)
Aug-19-24 07:00AM
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
(GlobeNewswire)
Aug-09-24 09:55AM
Does Supernus (SUPN) Have the Potential to Rally 28.65% as Wall Street Analysts Expect?
(Zacks)
Aug-06-24 08:00PM
Supernus (SUPN) Reports Q2 Earnings: What Key Metrics Have to Say
(Zacks) +14.49%
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005, and is headquartered in Rockville, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FRANK MOTTOLAOfficerSep 12 '25Proposed Sale45.875,000229,338Sep 12 04:05 PM
Khattar Jack A.President, CEOSep 08 '25Option Exercise25.308,074204,2721,118,305Sep 09 04:21 PM
Khattar Jack A.President, CEOSep 08 '25Sale46.296,322292,6451,111,983Sep 09 04:21 PM
Khattar Jack A.President, CEOSep 05 '25Option Exercise25.3073,1761,851,3531,165,809Sep 08 04:31 PM
Khattar Jack A.President, CEOSep 05 '25Sale46.0155,5782,557,1441,110,231Sep 08 04:31 PM
JACK A KHATTAROfficerSep 08 '25Proposed Sale46.006,322290,812Sep 08 04:28 PM
JACK A KHATTARDirectorSep 05 '25Proposed Sale45.4355,5782,524,909Sep 05 04:25 PM
Khattar Jack A.President, CEOAug 28 '25Option Exercise12.9838,779503,3511,116,783Aug 29 04:05 PM
Khattar Jack A.President, CEOAug 27 '25Option Exercise12.9817,195223,1911,088,654Aug 29 04:05 PM
Khattar Jack A.President, CEOAug 28 '25Sale45.1224,1501,089,6481,092,633Aug 29 04:05 PM
Khattar Jack A.President, CEOAug 27 '25Sale45.0510,650479,7821,078,004Aug 29 04:05 PM
NEWHALL CHARLES W IIIDirectorAug 27 '25Sale45.013,588161,496129,644Aug 29 04:05 PM
JACK A KHATTARDirectorAug 28 '25Proposed Sale45.0724,1501,088,440Aug 28 04:23 PM
Bhatt Padmanabh P.Sr. VP of IP, CSOAug 25 '25Option Exercise0.001,250014,299Aug 27 05:01 PM
Mottola FrankSVP, Quality, GMP, Ops, ITAug 25 '25Option Exercise12.9814,000181,72029,496Aug 27 04:59 PM
Mottola FrankSVP, Quality, GMP, Ops, ITAug 25 '25Sale44.5114,000623,14015,496Aug 27 04:59 PM
NEWHALL CHARLES W IIIDirectorAug 25 '25Sale45.001,00045,000133,232Aug 27 04:56 PM
Khattar Jack A.President, CEOAug 25 '25Option Exercise12.981,61120,9111,072,459Aug 27 04:56 PM
Khattar Jack A.President, CEOAug 25 '25Sale45.001,00045,0001,071,459Aug 27 04:56 PM
JACK A KHATTARDirectorAug 27 '25Proposed Sale44.3210,650472,008Aug 27 04:28 PM
NEWHALL CHARLES W IIIDirectorAug 22 '25Sale45.001,41263,540134,232Aug 26 04:19 PM
DEC TIMOTHY CSenior Vice-President & CFOAug 22 '25Sale44.4911,780524,0921,246Aug 26 04:18 PM
Khattar Jack A.President, CEOAug 22 '25Option Exercise12.982,41531,3471,072,348Aug 26 04:08 PM
Khattar Jack A.President, CEOAug 22 '25Sale45.001,50067,5001,070,848Aug 26 04:08 PM
JACK A KHATTARDirectorAug 25 '25Proposed Sale44.881,00044,880Aug 25 04:38 PM
CHARLES NEWHALLDirectorAug 25 '25Proposed Sale44.884,588205,909Aug 25 04:37 PM
FRANK MOTTOLAOfficerAug 25 '25Proposed Sale44.5114,000623,070Aug 25 04:09 PM
CHARLES NEWHALLDirectorAug 22 '25Proposed Sale43.321,41261,168Aug 22 05:04 PM
JACK A KHATTARDirectorAug 22 '25Proposed Sale43.321,50064,980Aug 22 04:47 PM
TIMOTHY CARROLL DECOfficerAug 22 '25Proposed Sale44.4911,780524,133Aug 22 04:26 PM
Sensenig BethanyDirectorAug 14 '25Sale42.255,369226,8400Aug 18 04:31 PM
Hudson Frederick M.DirectorAug 14 '25Sale42.267,457315,13346,307Aug 18 04:28 PM
FREDERICK M HUDSONDirectorAug 14 '25Proposed Sale42.267,457315,116Aug 14 04:33 PM
BETHANY SENSENIGDirectorAug 14 '25Proposed Sale42.645,369228,934Aug 14 04:22 PM
Khattar Jack A.President, CEOAug 06 '25Option Exercise17.95201,2503,613,2251,133,433Aug 08 04:40 PM
Khattar Jack A.President, CEOAug 06 '25Sale42.02140,0005,883,3601,030,183Aug 08 04:40 PM
JACK A KHATTARDirectorAug 06 '25Proposed Sale37.53140,0005,254,200Aug 06 04:23 PM
Khattar Jack A.President, CEOMar 10 '25Option Exercise0.0035,00001,008,638Mar 11 04:17 PM
DEC TIMOTHY CSenior Vice-President & CFOMar 10 '25Option Exercise0.003,800013,636Mar 11 04:15 PM
Khattar Jack A.President, CEOMar 07 '25Option Exercise0.0038,6400992,219Mar 07 04:40 PM
Mottola FrankSVP, Quality, GMP, Ops, ITMar 07 '25Option Exercise0.002,625016,507Mar 07 04:34 PM
Mottola FrankSVP, Quality, GMP, Ops, ITFeb 26 '25Option Exercise0.005,760017,683Feb 26 05:56 PM
Bhatt Padmanabh P.Sr. VP of IP, CSOFeb 21 '25Option Exercise0.001,650011,799Feb 24 08:22 PM
Rubin JonathanSVP, Chief Medical OfficerFeb 21 '25Option Exercise0.001,87508,780Feb 24 08:20 PM
Rubin JonathanSVP, Chief Medical OfficerFeb 21 '25Sale39.1592736,2927,853Feb 24 08:20 PM
Mottola FrankSVP, Quality, GMP, Ops, ITFeb 21 '25Option Exercise0.001,12509,576Feb 24 08:18 PM
Bhatt Padmanabh P.Sr. VP of IP, CSOFeb 04 '25Option Exercise29.619,477280,61419,626Feb 05 04:37 PM
Bhatt Padmanabh P.Sr. VP of IP, CSOFeb 04 '25Sale39.709,477376,23710,149Feb 05 04:37 PM
Bhatt Padmanabh P.Sr. VP of IP, CSOJan 27 '25Option Exercise29.612,57376,18712,722Jan 29 05:04 PM
Bhatt Padmanabh P.Sr. VP of IP, CSOJan 28 '25Option Exercise29.6170020,72710,849Jan 29 05:04 PM
Bhatt Padmanabh P.Sr. VP of IP, CSOJan 27 '25Sale39.622,573101,94210,149Jan 29 05:04 PM
Bhatt Padmanabh P.Sr. VP of IP, CSOJan 28 '25Sale39.6270027,73410,149Jan 29 05:04 PM
PADMANABH BHATTOfficerJan 27 '25Proposed Sale38.5522,000848,100Jan 27 04:26 PM
Hudson Frederick M.DirectorJan 22 '25Option Exercise9.1320,000182,60048,395Jan 23 04:33 PM
Rubin JonathanSVP, Chief Medical OfficerDec 27 '24Option Exercise0.002,62507,416Dec 30 04:13 PM
Khattar Jack A.President, CEODec 27 '24Option Exercise0.0052,6400964,812Dec 30 04:08 PM
Bhatt Padmanabh P.Sr. VP of IP, CSODec 03 '24Option Exercise24.7721,495532,36122,424Dec 04 04:36 PM
Bhatt Padmanabh P.Sr. VP of IP, CSODec 03 '24Sale36.6821,495788,4379,679Dec 04 04:36 PM
PADMANABH P BHATTOfficerDec 03 '24Proposed Sale37.3121,495801,978Dec 03 04:31 PM
NEWHALL CHARLES W IIIDirectorNov 11 '24Option Exercise9.1320,000182,600140,975Nov 12 04:15 PM
NEWHALL CHARLES W IIIDirectorNov 11 '24Sale36.2410,700387,768130,275Nov 12 04:15 PM
Hudson Frederick M.DirectorNov 08 '24Sale36.288,722316,43428,395Nov 12 04:14 PM
GEMAYEL GEORGESDirectorNov 08 '24Option Exercise11.4610,787123,61924,102Nov 12 04:13 PM
GEMAYEL GEORGESDirectorNov 08 '24Sale36.3010,787391,56813,315Nov 12 04:13 PM
Khattar Jack A.President, CEONov 08 '24Option Exercise9.13125,0001,141,2501,051,172Nov 12 04:11 PM
Khattar Jack A.President, CEONov 08 '24Sale36.29125,0004,536,250926,172Nov 12 04:11 PM
CHARLES NEWHALLOfficerNov 11 '24Proposed Sale36.2410,700387,775Nov 12 09:18 AM
JACK A KHATTAROfficerNov 08 '24Proposed Sale36.29125,0004,535,850Nov 08 05:00 PM
FREDERICK M HUDSONDirectorNov 08 '24Proposed Sale36.288,722316,476Nov 08 04:33 PM
GEORGES GEMAYELDirectorNov 08 '24Proposed Sale36.3010,787391,536Nov 08 04:19 PM
Mottola FrankSVP, Quality, GMP, Ops, ITNov 07 '24Option Exercise9.1315,000136,95023,200Nov 08 04:13 PM
Mottola FrankSVP, Quality, GMP, Ops, ITNov 07 '24Sale36.9815,000554,7008,200Nov 08 04:13 PM
GEMAYEL GEORGESDirectorNov 07 '24Option Exercise11.4614,213162,88127,528Nov 08 04:11 PM
GEMAYEL GEORGESDirectorNov 07 '24Sale36.6214,213520,48013,315Nov 08 04:11 PM
Khattar Jack A.President, CEONov 07 '24Option Exercise9.13125,0001,141,2501,051,172Nov 08 04:08 PM
Khattar Jack A.President, CEONov 07 '24Sale36.68125,0004,585,000926,172Nov 08 04:08 PM
JACK A KHATTAROfficerNov 07 '24Proposed Sale36.68125,0004,584,600Nov 07 04:59 PM
FRANK MOTTOLAOfficerNov 07 '24Proposed Sale36.9815,000554,692Nov 07 04:55 PM
GEORGES GEMAYELDirectorNov 07 '24Proposed Sale36.6214,213520,511Nov 07 04:42 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.